as were patients who ceased smoking prior to Dx c/w patients who quit at Dx (p = 0.045). B2/B3 disease was more likely if iv steroids (p = 0.004), IS (p < 0.0001) were required or if there was perianal disease (p < 0.0001). 558 patients required intestinal surgery and modelling with smoking status as a predictor showed that smoking was significant (p = 0.044). Multivariate analysis showed surgery was more common with TI (p < 0.0001) and perianal (p = 0.01) disease, while smoking lost significance. 186 patients underwent a 2nd intestinal resection. A greater proportion of smokers underwent a 2nd surgical resection (401%) than patients who quit at, or before, the 1st surgical resection (29%) and NS (28%) but was not significant. There was a general trend in disease behaviour change and the need for 1st and 2nd surgery with increasing numbers of cigarettes/day smoked. Regression analysis identified cigarettes/day smoked as significantly associated with B2/B3 disease change (0.01). Conclusions: Smoking is a modifiable risk factor. Cessation at Dx reduces the rate of complicated disease as does reducing the number of cigarettes/day smoked. This supports the need for CD patients to be strongly encouraged to cease or at least reduce their smoking.
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Skin pathology associated with anti-tumournecrosis factor (anti-TNF) therapy a single UK IBD centre experience Background: With the increasing use of biologic therapy in the treatment of inflammatory bowel disease (IBD) there has been a reported increase in dermatological conditions associated with therapy in patients with IBD. We carried out a prospective audit to identify the proportion of IBD patients at The Royal Free Hospital on anti-TNF therapy developing therapy related inflammatory skin pathology. Methods: 141 IBD patients on anti-TNF therapy (either infliximab or adalimumab) were sent a postal questionnaire to identify patients who had experienced identifiable and associated skin conditions. The questionnaire included information regarding the body site affected, dermatology opinion and whether therapy had to be stopped. Data for infliximab and adalimumab were analysed. Results: Of 141 patients, 105 replied (71 (74%) infliximab and 34 (74%) adalimumab). In both groups 32% of patients described new skin complaints attributable to anti-TNF therapy (n = 23 in infliximab group, n = 11 in adalimumab group). Sites of skin inflammation were common to both groups; face (29%), trunk (21%), legs (14%) and arms (14%). Combined data showed only 44% of patients were reviewed by a dermatologist and received a formal diagnosis. No patients on adalimumab stopped treatment, while 3 stopped therapy in the infliximab group (9% overall). Conclusions: Although IBD is itself associated with skin pathology, recent studies have demonstrated that patients on anti-TNF therapy develop inflammation of the skin [1], and our data support the concept that paradoxical skin inflammation related to anti-TNF therapy is a class effect. In our cohort few patients had to stop therapy which is similar to some [1], but not all reported studies [2, 3] . Less than half of affected patients received consultant dermatological review. Background: In inflammatory bowel diseases, thiopurine metabolites measurement; 6-thioguanine nucleotide and 6-methyl mercaptopurine, has been proposed to explain its therapeutic failure and toxicity. The levels associated with efficacy is 235 450 pmol/8×10 8 for 6-TGN and hepatotoxicity for 6MMP is >5700 pmol/8×10
8 . There is a scarcity of guidelines in terms of the timing of measurement. Thus, determining the effect of measuring thiopurine metabolites on subsequent management strategy during disease flare and remission would be useful. Methods: Metabolites were performed on consecutive IBD patients on thiopurines and their medical records reviewed. Disease activity at the time of metabolite measurements (categorised to "flare" or "remission" based on blood tests, endoscopy and physician assessment) and any subsequent management decision (thiopurine dose increase/adjust, use of allopurinol, therapy escalation, no action) were assessed. Weight-based dosing (calculated at 1 mg/kg 6-Mercaptopurine, 2 mg/kg Azathioprine) were compared to metabolite-determined thiopurine maintenance dose. Results: In total, 30.9% of patients (44/142) reviewed were on thiopurines and 126 metabolites levels were measured from 2008 to 2012. Of these, 47.6% (60/126) were done during disease flare and 52.3% (66/126) during remission. Measurement of thiopurine metabolites was subsequently followed by increasing/adjusting thiopurine dose in 38% (23/60) during flare and 13.6% of tests (9/66) during remission (OR = 2.81, 95% CI: 1.13 7.42; p = 0.01). 15% (9/60) and 4.5% (3/66) of patients were identified as metabolite 'shunters' and started on allopurinol during flare and remission, respectively (p < 0.001). Therapy escalation (ie. biological agent, drug trial, surgery) followed metabolites measurement in 20% (12/60) during flare and 0% of tests (0/66) during remission. No action was taken after 26.6% (16/60) and 81.8% (54/66) (OR = 3.07, 95% CI: 1.53 6.34; p < 0.001) of tests when done during flare and remission, respectively. 68% (30/44) of patients were on a lesser thiopurine dose when determined by metabolites level as supposed to weight. On average, patients on 6-MP were taking 48% less (71.2% less on 6-MP/allopurinol) and patients on azathioprine 27.1% less dose (70% lower on azathioprine/allopurinol). Conclusions: Metabolites measurement during IBD flare plays a useful role prior to management change. Metabolite-based thiopurine dosing may allow more patients to be on thiopurine due to potentially less toxicity risk.
